SM
AVDL

SG3 Management’s Avadel Pharmaceuticals AVDL Stock Holding History

SG3 Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-48,000
Closed -$388K – 958
2021
Q4 		$388K Sell
48,000
-3,313
-6% -$30.3K 0.01% 685
2021
Q3 		$503K Buy
51,313
+16,313
+47% +$128K 0.02% 597
2021
Q2 		$236K Sell
35,000
-15,000
-30% -$119K 0.01% 794
2021
Q1 		$452K Buy
+50,000
New +$404K 0.01% 804

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

SG3 Management's AVDL Position: Q1 2022 in Review

SG3 Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2022, closing a stake of 48,000 shares — an estimated $388K sold.

SG3 Management first reported a position in AVDL in Q1 2021 and held it in 4 quarters. The position peaked at $503K in Q3 2021. 81 funds tracked by Wall St. Rank hold AVDL as of Q1 2022.

  • SG3 Management reported no remaining Avadel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • SG3 Management sold 48,000 Avadel Pharmaceuticals shares in Q1 2022, an estimated $388K.
  • SG3 Management first reported a position in Avadel Pharmaceuticals in Q1 2021 and held it in 4 quarters.
  • SG3 Management's Avadel Pharmaceuticals position peaked at $503K in Q3 2021.
  • 81 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.